EGFR and non-small cell lung carcinoma: Therefore, we included randomized controlled trials (RCTs) and single-arm phase 2 studies, and conducted a meta-analysis to compare the efficacy and safety of these regimens at study level and individual patient level to determine the optimal treatment option for EGFR-TKI-resistant patients with NSCLC.